Georgievski, Borche
Preferred name
Georgievski, Borche
Official Name
Georgievski, Borche
Main Affiliation
Email
borche.georgievski@medf.ukim.edu.mk
81 results
Now showing 1 - 10 of 81
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Treatment of Severe Autoimmune Diseases with Autologous Hematopoietic Stem Cell Transplantation(Македонско лекарско друштво = Macedonian medical association, 2017-01-01); ; ; Cadievski, Lazar<jats:title>Abstract</jats:title> <jats:p><jats:bold>Introduction.</jats:bold> Autoimmune diseases are a family of more than 100 heterogeneous conditions that affect 5 to 8% of the world’s population. The etiology is still un-known but the disregulation of the regulatory T-lymphocytes play a central role inthe autoimmunity and the success of the long-term remission. Although conventional immunosuppression and new biological agents can provide disease control in severely affected patients, such treatments are rarely curative and alternative strategies are needed. Indeed, severe forms of systemic autoimmune diseases, such as multiple sclerosis (MS), systemic sclerosis (SSc), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), juvenile idiopathic arthritis (JIA), hematologic immune cytopenia (HIC) and Crohn’s disease are difficult to be treated. High-dose immunosuppressive therapy followed by autologous stem cells transplantation is reliable option for a successive treatment of this group of patients.</jats:p> <jats:p><jats:bold>Aim.</jats:bold> To determine the safety of the procedure of autologous stem cell transplantation in patients with autoimmune diseases and concomitant malignant hematological disorders.</jats:p> <jats:p><jats:bold>Methods.</jats:bold> During a period of 15 years (from September 2000 to September 2015) at the University Clinic of Hematology in Skopje we have treated 6 patients with autoimmune disease and concomitant hematological neoplasm. None of the patients was treated for primary autoimmune diseases. Two men and 4 women, with median age of 47 years were treated. Sjogren syndrome and multiple myeloma were found in 2 patients, polyartheritis nodosa and multiple myeloma in 1 patient, rheumatoid arthritis and acute myeloblastic leukemia in 1, systemic lupus erythematosus and non-Hodgkin lymphoma in 1; severe psoriasis and acute myeloblastic leukemia in 1 patient.</jats:p> <jats:p><jats:bold>Results.</jats:bold> All treated patients are alive after trans-planted procedure, with transplant related mortality day +100: 0.</jats:p> <jats:p><jats:bold>Conclusion.</jats:bold> Autologous stem cell transplantation is safe and recommended option for treatment ofpatients with autoimmune disease and hematologic neoplasm.</jats:p> - Some of the metrics are blocked by yourconsent settings
Item type:Publication, P062 Results of RCHOP6 or RCHOP8 study in the treatment of patients with diffuse large B-cell lymphoma – single institution study(Elsevier BV, 2007-09); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Прогностичко одредување на исходот од лекување со автологна трансплантација на матични хематопоетски клетки(SHMSHM - AAMD, 2012); ; ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Antifungal Prophylaxis In Hematopoietic Stem Cell Transplant Recipients(Scientific Foundation SPIROSKI, 2008-09-01); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Antimycotic prophylaxis in stem cell recipients – single center expirience(Elsevier, 2007-09); ; ; Ivanovski Martin - Some of the metrics are blocked by yourconsent settings
Item type:Publication, IPI In Selecting Patients With Diffuse Large B Cell Lymphoma in Rituximab Era(American Society of Hematology, 2013-11-15); ; ; <jats:title>Abstract</jats:title> <jats:p>Nowadays, goal of treatment approach in diffuse large B cell lymphoma is cure and first step towards it is to achieve complete remission. DLBCL is a potentially curable disease, with curability highly dependent on clinical and biological features. According to the WHO classification of Hematological Malignancies, the entity of DLBCL is characterized by rapidly growing mature B cell tumors with large or relatively large cells and /includes a number of disease variants/entities / encompassing several distinct clinopathologic diseases, several different histologic variants and clinical subtypes. There is no unique treatment for all patients with diffuse large B cell lymphoma. Different subgroup of patients with DLBCL needs different treatment. In the pre-rutuximab era International Prognostic Index (IPI) was considered to be the most important prognostic factor for survival and the strongest indicator for identification of high-risk patients, who are unlikely to be cured with standard chemotherapy. Having in mind that IPI is based on 5 clinical characteristics (age, performance status, stage, extranodal involvement, LDH level) and it is constructed in the pre-rituximab is clear that R-IPI should be tested in rituximab era to provide any information of its validity.</jats:p> <jats:p>We retrospectively analyzed unselected population of 80 patients with confirmed diagnose of diffuse large B cell lymphoma treated at University hematology department in the period of 2005-2010. All patients were uniformly treated with R-CHOP regiment as initial treatment with curative intent. There were 80 patients with mean age 54, 5 years (15-84), male 35 and female 45. Older than 60 years were 29 patients (36, 25%). More than half of the patients (42) were diagnosed in advanced stage of the disease. We analyzed five prognostic factors: age, performance status, stage, extranodal involvement, LDH level and through the multifactorial analyses we selected two groups of patients. One with 0 to 2 factors as patients with low risk. Patients with more than 3 factors are considered as high risk. There is statistically significant difference in overall survival between two groups with five –years overall survival 70% for low risk patients and 47% for high risk. High-risk patients may be candidates for autologous transplantation as initial treatment, having in mind that in the rituximab era relapses occur very early in the first year and are difficult to be treated.</jats:p> <jats:p>R-IPI score is significant predictor and should be used for risk stratification of patients with aggressive B-cell lymphoma. However, these findings should be validated prospectively in an independent population of patients.</jats:p> <jats:sec> <jats:title>Disclosures:</jats:title> <jats:p>No relevant conflicts of interest to declare.</jats:p> </jats:sec> - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Chronic Graft-Versus Host Disease - Single Center Experience(Scientific Foundation SPIROSKI, 2008-09-01); ; ; ; Gocev, Georgi - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Cryopreservation of autologous peripheral blood stem cells - presence and future directions(Macedonian Association of Anatomists and Morphologists, 2015); ; ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Lamivudine treatment for acute hepatitis B virus infection during allogeneic peripheral blood stem cell transplantation(Springer Science and Business Media LLC, 2003-03); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Clinical Significance of Bcl-2 and Ki67 Protein Expression in Agrressive Non-Hodgkin Lymphoma(American Society of Hematology, 2004-11-16);